Call for Papers  

Article Details

Review Article

Syndecan-1 (CD138) as a Pathogenesis Factor and Therapeutic Target in Breast Cancer

[ Vol. 28 , Issue. 25 ]


Mona Sheta and Martin Götte*   Pages 5066 - 5083 ( 18 )


The successive stages of breast cancer growth and dissemination depend on cell-autonomous factors and the communication between tumor cells and their surrounding cellular and extracellular matrix microenvironment. The cell surface heparan sulfate proteoglycan Syndecan-1 is dysregulated both in tumor cells and cells of the breast tumor stroma, indicating a potential role in the pathogenesis of this most frequent malignancy in women. Indeed, Syndecan-1 interacts with numerous ligands and receptors relevant to tumor progression, affecting processes as diverse as cancer stem cell function, cell proliferation, apoptosis, cell adhesion, migration and invasion, tumor angiogenesis, and leukocyte function in the tumor stroma. The present review summarizes the current understanding of breast carcinogenesis in correlation with their Syndecan-1 expression, involved mechanisms, and proposed therapeutic strategies against Syndecan-1-related malignancy.


Syndecan, proteoglycan, breast cancer, prognosis, therapeutic target, prognostic marker, heparan sulfate, extracellular matrix.


Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Department of Gynecology and Obstetrics, Münster University Hospital, Münster

Read Full-Text article